Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3052921rdf:typepubmed:Citationlld:pubmed
pubmed-article:3052921lifeskim:mentionsumls-concept:C0018823lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C0019010lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C1317973lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C0445204lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C0183683lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C0344211lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C1521721lld:lifeskim
pubmed-article:3052921lifeskim:mentionsumls-concept:C1171411lld:lifeskim
pubmed-article:3052921pubmed:issue5 Pt 2lld:pubmed
pubmed-article:3052921pubmed:dateCreated1988-12-15lld:pubmed
pubmed-article:3052921pubmed:abstractTextThe accessibility and success of cardiac transplantation promotes transplantation for a broad range of recipients, including those requiring intravenous inotropes or mechanical-assist devices. To determine if survival is dependent on preoperative requirements for hemodynamic support, we studied 230 patients who underwent transplant at the Loyola, Stanford, and UTAH programs from December 1, 1984 through November 30, 1986, and who were followed up for 34 months postoperatively. Group 1 (n = 132 of 230, 57%) patients required only oral medical therapy to maintain hemodynamic compensation; Group 2 (n = 69 of 230, 30%) patients were dependent on intravenous inotropic support; and Group 3 (n = 29 of 230, 13%) patients required mechanical assistance. Pretransplant characteristics showed that dilated cardiomyopathy was more common in Group 2 patients, and lower cardiac index and ejection fraction were more prevalent in Group 3 patients as expected. Although survival was lower in Group 3 only at 1 month (Group 1, 98.5%; Group 2, 92.8%; and Group 3, 86.2%; p less than 0.01), the survival advantage in Groups 1 and 2 was lost by 3 months, with 1-year survival rates of 88.6% in Group 1, 81.2% in Group 2, and 82.8% in Group 3. Allograft survival and cause of death were not different among the three groups. Acute rejection occurred at a lower monthly frequency in the first 4 months in Group 3 (Group 1, 0.47 +/- 0.03; Group 2, 0.47 +/- 0.05; and Group 3, 0.29 +/- 0.06; p less than 0.01), whereas infectious complications occurred at similar frequencies.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3052921pubmed:languageenglld:pubmed
pubmed-article:3052921pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3052921pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3052921pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3052921pubmed:statusMEDLINElld:pubmed
pubmed-article:3052921pubmed:monthNovlld:pubmed
pubmed-article:3052921pubmed:issn0009-7322lld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:RobinsonJ AJAlld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:OyerP EPElld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:GayW AWAJrlld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:PifarréRRlld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:O'ConnellJ...lld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:RenlundD GDGlld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:GradyK LKLlld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:MenloveR LRLlld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:FowlerM BMBlld:pubmed
pubmed-article:3052921pubmed:authorpubmed-author:MullinA VAVlld:pubmed
pubmed-article:3052921pubmed:issnTypePrintlld:pubmed
pubmed-article:3052921pubmed:volume78lld:pubmed
pubmed-article:3052921pubmed:ownerNLMlld:pubmed
pubmed-article:3052921pubmed:authorsCompleteNlld:pubmed
pubmed-article:3052921pubmed:paginationIII78-82lld:pubmed
pubmed-article:3052921pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:meshHeadingpubmed-meshheading:3052921-...lld:pubmed
pubmed-article:3052921pubmed:year1988lld:pubmed
pubmed-article:3052921pubmed:articleTitleEffect of preoperative hemodynamic support on survival after cardiac transplantation.lld:pubmed
pubmed-article:3052921pubmed:affiliationUTAH Cardiac Transplant Program, University of Utah Health Sciences Center, Salt Lake City 84132.lld:pubmed
pubmed-article:3052921pubmed:publicationTypeJournal Articlelld:pubmed